Halozyme Therapeutic (HALO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2010 | 09-2010 | 06-2010 | 03-2010 | 12-2009 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -53,242 | -36,348 | -23,938 | -11,788 | -58,361 |
| Depreciation Amortization | 1,508 | 1,164 | 800 | 410 | 1,444 |
| Accounts receivable | 1,916 | 1,622 | 1,990 | 2,223 | 3,021 |
| Other Working Capital | 1,468 | -6,581 | -5,686 | -2,459 | 12,240 |
| Other Operating Activity | 2,964 | 2,133 | 440 | -989 | 1,508 |
| Operating Cash Flow | $-45,386 | $-38,010 | $-26,394 | $-12,603 | $-40,148 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -647 | -316 | -255 | -149 | -1,461 |
| Investing Cash Flow | $-647 | $-316 | $-255 | $-149 | $-1,461 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 61,823 | 60,702 | 498 | 464 | 45,358 |
| Financing Cash Flow | $61,823 | $60,702 | $498 | $464 | $45,358 |
| Beginning Cash Position | 67,465 | 67,465 | 67,465 | 67,465 | 63,716 |
| End Cash Position | 83,256 | 89,841 | 41,312 | 55,176 | 67,465 |
| Net Cash Flow | $15,791 | $22,376 | $-26,152 | $-12,288 | $3,749 |
| Free Cash Flow | |||||
| Operating Cash Flow | -45,386 | -38,010 | -26,394 | -12,603 | -40,148 |
| Capital Expenditure | -647 | -316 | -255 | -149 | -1,461 |
| Free Cash Flow | -46,032 | -38,326 | -26,650 | -12,752 | -41,609 |